Intravenous tissue plasminogen activator (tPA) has become the only medication approved by FDA for AIS and can salvage dying cells from the ischemic penumbra, but it should be administered within 4.5 h of stroke onset, and the delayed tPA infusion would increase the hemorrhagic transformation [4, 5]. The gene discussed is PLAT; the disease is stroke disorder.